Multicenter randomized double-blind parallel-group add-on superiority study to

Recruiting

99 years or below

All

Phase 3

6 participants needed

1 Location

Brief description of study

This is a study to find out whether patients with active forms of Relapsing Multiple Sclerosis (RMS) who are treated with dimethyl fumarate (Tecfidera®) can be treated better by the addition of ponesimod (study drug). The purpose is also to evaluate the effect on disability and the safety of these two drugs together in comparison to Tecfidera® alone (plus placebo).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: ['Breast Cancer', 'Hereditary Breast/Ovarian Cancer (brca1, brca2)', 'Heart Diseases', 'Drug-Induced Cardiomyopathy']
Age: 99 years or below
Gender: All

Updated on 19 Feb 2024. Study ID: 828873

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

Brief description of study

Eligibility of study

Find a site